1. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study (NordCML006). (13th September 2014) Authors: Hjorth‐Hansen, Henrik; Stenke, Leif; Söderlund, Stina; Dreimane, Arta; Ehrencrona, Hans; Gedde‐Dahl, Tobias; Gjertsen, Bjørn Tore; Höglund, Martin; Koskenvesa, Perttu; Lotfi, Kourosh; Majeed, Waleed; Markevärn, Berit; Ohm, Lotta; Olsson‐Strömberg, Ulla; Remes, Kari; Suominen, Merja; Simonsson, Be... Journal: European journal of haematology Issue: Volume 94:Number 3(2015:Mar.) Page Start: 243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Issue 6 (June 2018) Authors: Saussele, Susanne; Richter, Johan; Guilhot, Joelle; Gruber, Franz X; Hjorth-Hansen, Henrik; Almeida, Antonio; Janssen, Jeroen J W M; Mayer, Jiri; Koskenvesa, Perttu; Panayiotidis, Panayiotis; Olsson-Strömberg, Ulla; Martinez-Lopez, Joaquin; Rousselot, Philippe; Vestergaard, Hanne; Ehrencrona, Han... Journal: Lancet oncology Issue: Volume 19:Issue 6(2018) Page Start: 747 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Imatinib and pegylated IFN‐α2b discontinuation in first‐line chronic myeloid leukemia patients following a major molecular response. (28th January 2014) Authors: Koskenvesa, Perttu; Kreutzman, Anna; Rohon, Peter; Pihlman, Markus; Vakkila, Emmi; Räsänen, Anu; Vapaatalo, Mirja; Remes, Kari; Lundán, Tuija; Hjorth‐Hansen, Henrik; Vakkila, Jukka; Simonsson, Bengt; Mustjoki, Satu; Porkka, Kimmo Journal: European journal of haematology Issue: Volume 92:Number 5(2014:May) Page Start: 413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. (2nd September 2019) Authors: Kreutzman, Anna; Yadav, Bhagwan; Brummendorf, Tim H.; Gjertsen, Bjorn Tore; Hee Lee, Moon; Janssen, Jeroen; Kasanen, Tiina; Koskenvesa, Perttu; Lotfi, Kourosh; Markevärn, Berit; Olsson-Strömberg, Ulla; Stentoft, Jesper; Stenke, Leif; Söderlund, Stina; Udby, Lene; Richter, Johan; Hjorth-Hansen, He... Journal: Oncoimmunology Issue: Volume 8:Number 9(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study. (26th April 2016) Authors: Kekäle, Meri; Söderlund, Tim; Koskenvesa, Perttu; Talvensaari, Kimmo; Airaksinen, Marja Journal: Journal of advanced nursing Issue: Volume 72:Number 9(2016:Sep.) Page Start: 2196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy. Issue 4 (April 2014) Authors: Ilander, Mette; Koskenvesa, Perttu; Hernesniemi, Sari; Lion, Thomas; Porkka, Kimmo; Mustjoki, Satu Journal: Leukemia & lymphoma Issue: Volume 55:Issue 4(2014:Apr.) Page Start: 934 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study. (31st August 2021) Authors: Flygt, Hjalmar; Söderlund, Stina; Stentoft, Jesper; Richter, Johan; Koskenvesa, Perttu; Mustjoki, Satu; Majeed, Waleed; Lübking, Anna; Dreimane, Arta; Markevärn, Berit; Stenke, Leif; Myhr Eriksson, Kristina; Gjertsen, Bjørn Tore; Gedde‐Dahl, Tobias; Dimitrijevic, Andreja; Udby, Lene; Olsson‐Ström... Journal: European journal of haematology Issue: Volume 107:Number 6(2021) Page Start: 617 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy. (March 2020) Authors: Söderlund, Stina; Persson, Inger; Ilander, Mette; Guilhot, Joëlle; Hjorth-Hansen, Henrik; Koskenvesa, Perttu; Richter, Johan; Saussele, Susanne; Mustjoki, Satu; Olsson-Strömberg, Ulla Journal: Leukemia research Issue: Volume 90(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Ponatinib‐induced ichthyosiform eruption. Issue 3 (14th May 2021) Authors: Kluger, Nicolas; Lappalainen, Katriina; Koskenvesa, Perttu Journal: EJHaem Issue: Volume 2:Issue 3(2021) Page Start: 659 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. Issue 11 (14th September 2019) Authors: Lauseker, Michael; Bachl, Katharina; Turkina, Anna; Faber, Edgar; Prejzner, Witold; Olsson‐Strömberg, Ulla; Baccarani, Michele; Lomaia, Elza; Zackova, Daniela; Ossenkoppele, Gert; Griskevicius, Laimonas; Schubert‐Fritschle, Gabriele; Sacha, Tomasz; Heibl, Sonja; Koskenvesa, Perttu; Bogdanovic, An... Journal: American journal of hematology Issue: Volume 94:Issue 11(2019:Nov.) Page Start: 1236 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗